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Abstract: Percutaneous pulmonary valve implantation (PPVI) is used to treat pulmonary stenosis (PS)
or pulmonary regurgitation (PR). We described our experience with PPVI, specifically valve-in-valve
transcatheter pulmonary valve replacement using the Melody valve and novel self-expandable
systems using the Pulsta valve. We reviewed data from 42 patients undergoing PPVI. Twenty-nine
patients had Melody valves in mostly bioprosthetic valves, valved conduits, and homografts in the
pulmonary position. Following Melody valve implantation, the peak right ventricle-to-pulmonary
artery gradient decreased from 51.3 ± 11.5 to 16.7 ± 3.3 mmHg and right ventricular systolic pressure
fell from 70.0 ± 16.8 to 41.3 ± 17.8 mmHg. Thirteen patients with native right ventricular outflow tract
(RVOT) lesions and homograft underwent PPVI with the new self-expandable Pulsta valve—a nitinol
wire stent mounted with a trileaflet porcine pericardial valve. Following Pulsta valve implantation,
cardiac magnetic resonance imaging showed a decreased PR fraction and that the right ventricular
end-diastolic volume index decreased from 166.1 ± 11.9 to 123.6 ± 12.4 mL/m2. There were no
mortality, severe procedural morbidity, or valve-related complications. At the mean 14.2 month
(4–57 months) follow-up, no patients had more than mild PR. PPVI using Melody and Pulsta valves
was first shown to provide excellent early outcomes without serious adverse event in most patients
with RVOT dysfunction in Korea.
Keywords: heart diseases; heart valve prosthesis; pulmonary heart disease; pulmonary valve; pediatrics
1. Introduction
Patients with either congenital or acquired heart diseases involving dysfunction of the right
ventricular outflow tract (RVOT) require implantation of a prosthetic valve, with or without a conduit,
between the right ventricle (RV) and the pulmonary artery (PA). This implantation is required for
significant pulmonary stenosis or pulmonary regurgitation (PR) and ventricular failure as well [1].
However, given that the inevitable degeneration of the artificial tissue of the prosthetic valves and
conduits results in clinically significant pulmonary regurgitation or stenosis, repetitive and multiple
surgical interventions turn out to be mandatory. Overall, this leads to greater scarring of the cardiac
and vascular tissues and an increased surgical risk. Furthermore, open-heart surgery is associated
with considerable psychological strain on the patient, as well as with morbidity and lengthy recovery
times [2].
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Percutaneous pulmonary valve implantation (PPVI) using Melody (Medtronic, Minneapolis, MN,
USA) and Edwards SAPIEN (Edwards Lifesciences, Irvine, CA, USA) valves has been used to replace
surgical pulmonary valve replacement and extend the lifespan of existing RVOT revisions to delay the
need for repeated surgical interventions [3]. This technique is considered the most appropriate first-line
approach to pulmonary valve replacement in selected patients [4]. Since its first implementation in
2000 by Bonhoeffer et al. [3] and subsequent approval by the Food and Drug Administration in 2010,
PPVI using the Melody and Edwards SAPIEN valves has been performed in more than 13,000 patients
with postoperative RVOT dysfunction worldwide. Indeed, surgically implanted RV-to-PA valves
and conduits are being replaced by balloon-expandable PPVIs, which showed excellent long-term
outcome by several reports [5–10]. However, recent advances such as valve-in-valve replacement
within dysfunctional bioprosthetic valves (BPVs) and smaller conduits in smaller patients (<30 kg),
or recognized factors for a better outcome such as the routine use of pre-stenting and the avoidance of
high post-interventional gradients across RVOT, are not uniformly applied to existing studies.
Concurrently the new larger valve of a self-expandable nature has been suggested as the next
generation of percutaneous valves in majority of patulous native RVOT lesions [11,12]. The Pulsta valve
(TaeWoong Medical Co, Gyeonggi-do, South Korea) is a novel, self-expandable valve with flared ends
that adapts well to a larger native RVOT. It uses a relatively low-profile delivery catheter with a knitted
nitinol wire backbone and trileaflets made from treated porcine pericardial tissue [13]. Since their
efficacy and safety were reported in a study published in 2018, cases of Pulsta valve implantation have
increased in South Korea [14].
In 2015, PPVI with Melody valves was performed for the first time in Korea in three patients at
our institution. Thereafter, improvements were observed in both the procedure and the perception of
the device by domestic congenital cardiologists. Recently, the use of both the Melody and Pulsta valves
has been approved by the Korean Food and Drug Administration. This is the first report discussing
the use of both valves to treat patients with PPVI. This study aimed to evaluate the early procedural
and clinical outcomes of PPVI using the Melody and Pulsta valves.
2. Experimental Section
2.1. Study Population
A total of 42 patients who underwent PPVI in a single tertiary referral center from August 2015 to
March 2020 were retrospectively enrolled in the current study. Criteria for a PPVI included the following:
moderate or substantial pulmonary regurgitation, indexed RV end-diastolic volume > 150 mL/m2,
indexed RV end-systolic volume > 80 mL/m2, or RV dysfunction (RV ejection fraction < 47%) as observed
on cardiac magnetic resonance image (MRI), and/or pulmonary stenosis (with a mean RVOT gradient ≥
35 mmHg) as measured by transthoracic echocardiography (TTE) [1,15,16]. Additional clinical features
were exercise intolerance, symptoms and signs of heart failure, syncope, and/or significant arrhythmia.
Finally, the patient’s anatomy was evaluated for the implantation of either the Melody or Pulsta valve
through TTE, cardiac computed tomography (CT), cardiac MRI, and cardiac angiography.
2.2. The Valves
2.2.1. The Melody Valve
The Melody valve is a transcatheter pulmonary valve (TPV) consisting of a bovine jugular
vein sutured inside a platinum iridium stent. Currently, two valve sizes are available, namely the
TPV 20 and 22. While the TPV 20 uses a 16 mm bovine jugular vein and is intended for 20 mm
diameter implantations, the TPV 22 uses an 18 mm bovine jugular vein intended for 22 mm diameter
implantations. Although the unexpanded valve heights are 30 and 28 mm for the TPV 20 and 22,
respectively, they are both deployed using the Medtronic Ensemble delivery system, which is a 22 F
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delivery system that uses balloon-in-balloon technology. Finally, this ensemble is available in three
sizes, i.e., 18, 20, and 22 mm [3,17].
2.2.2. The Pulsta Valve
The Pulsta valve is made of a knitted double-strand nitinol wire, and its stent wall is covered with
trileaflets made from treated porcine pericardial tissue. The valve diameter ranges from 18 to 32 mm
(with increments of 2 mm). Both ends of the valve are flared, rendering the valve 4 mm wider than its
outer diameter at its ends to ensure stable valve adaptation to various RVOT geometries. Therefore,
the total length of the valve varies between 28 and 38 mm, according to its outer diameter. While the
diameter of the outer sheath in the valve loading zone is 18 F (5.9 mm), that of the catheter shaft is 12 F.
Also, hooking the proximal end of the nitinol wires to the hook block simply allows for both controlled
deployment and subsequent good positioning of the valve at the target area [13,14].
2.3. Clinical Assessment
For the monitoring and assessment of patients’ outcome, we performed regular follow-up at
1 month, 3–6 months, 12 months, and annual visit after implantation. The primary outcome measures
were the feasibility and safety of valve implantation, determined in patients whose TPV had been
implanted for > 24 h; the outcome measure was a composite of the following evaluations: physical
assessments, exercise testing, cardiac MRI, and transthoracic echocardiography. The following factors
were measured to determine the hemodynamic and functional outcomes of implantation: RV and
PA systolic pressures (measured by cardiac catheterization), peak systolic gradient over the RVOT
(measured by Doppler recording on transthoracic echocardiography), degree of PR and TR (measured
by transthoracic echocardiography and cardiac MRI), indexed right ventricular end-diastolic volume
(RVEDVi) and RV ejection fraction (measured by cardiac MRI). In addition, follow-up data included
the changes in the New York Heart Association (NYHA) class, peak oxygen consumption (VO2),
anaerobic threshold (AT), device function, and evidence of structural valve deterioration, including
stent fracture. Safety outcomes were specifically defined as a result of device malfunction as well as
coronary compression, neurologic impairment, conduit/RVOT rupture, stent dislocation, bleeding
complications, need for surgical correction, endocarditis of the implanted valve, and any cardiovascular
events, including death, myocardial infarction, coronary compression, pulmonary embolism, and
stroke/transient ischemic attack.
2.4. Statistical Analysis
Frequency distributions are provided for categorical variables, and means with standard deviations
and medians with ranges are given for numerical variables. Statistical analyses were performed
using SPSS Statistics version 23.0 for Windows (SPSS Inc., Chicago, IL, USA). Paired t tests were
used to analyze changes in continuous variables between baseline and follow-up variables. Finally,
the Wilcoxon signed-rank test was used to compare variables between the baseline and follow-up
measurements. p-values less than 0.05 were considered statistically significant.
2.5. Ethics Statement
This study was approved by the Yonsei University College of Medicine Institutional Review Board
and the Research Ethics Committee of Severance Hospital (study approval number: 4-2020-0210).
All research was performed in accordance with relevant guidelines and regulations. The requirement
for written informed consent was waived by the Institutional Review Board due to the retrospective
study design.
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3. Results
3.1. Patient Characteristics
The majority of patients were male (71.4%), with a mean age of 27.2 ± 13.5 years (median:
23 years old, range: 9.5–75 years). Baseline patient characteristics prior to the procedure are described
in Table 1. Among the 42 patients, twelve presented with a native RVOT anatomy and 1 with a
pulmonary homograft 26 mm prior to PPVI (31.0%) with the Pulsta valve, 28 demonstrated stented
bioprosthetic valves and conduits for the most common RVOT anatomy findings prior to implantation
of the Melody valve (e.g., Carpentier-Edwards, Hancock, Saint Jude Epic; 28/42, 66.7%), and one case
of pulmonary homograft was also observed. Moreover, 29 patients showed an above-moderate RVOT
obstruction, which corresponded to the eligibility criteria for the implantation procedure. The thirteen
patients who opted for the Pulsta valve presented with severe PR, with a mean PR fraction derived
by cardiac MRI of 46.7% ± 8.0% (range: 38.0–59.0%). Meanwhile, the patients using the Melody
valves showed a mean PR fraction of 17.1% ± 13.6% (range: 1.2–40.2%) better than Pulsta valve group
(p = 0.02). The mean indexed RV end-diastolic volume was 166.1 ± 11.9 mL/m2, as observed with
cardiac MRI in Pulsta valve patients, significantly larger than that in patients with the Melody valve
(137.5 ± 31.1, p = 0.04). Furthermore, all patients showed mild-to-moderate exercise intolerance during
cardiopulmonary exercise assessments, with a mean peak oxygen consumption of 28.1 ± 4.7 mL/kg/min
(range: 19.4–36.1 mL/kg/min). Finally, most patients belonged to either NYHA class II (24/42, 57.1%) or
III (11/42, 26.2%) at baseline.
Table 1. Patient characteristics.
n/N (%) or Mean ± SD (Range)
Age, years 27.2 ± 13.5 (9.5–75)
Female 12/42 (28.6)
Weight, kg 61.8 ± 14.3 (31–92)
Height, cm 173.8 ± 7.4 (124–185)
Prior endocarditis 3/42 (7.1)
Underlying diagnosis
Tetralogy of Fallot 40/42 (95.2)
Pulmonary atresia with ventricular septal defect 2/42 (4.8)
RVOT anatomy prior to valve implantation
Native RVOT 12/42 (28.6)
Bioprosthetic valve 24/42 (57.1)
Valved conduit 4/42 (9.5)
Homograft 2/42 (4.8)
Percutaneous pulmonary valve implant
indication
RVOT obstruction 15/42 (35.7)
Mixed PR and obstruction 14/42 (33.3)
PR 13/42 (31.0)
Cardiopulmonary exercise function
Peak oxygen consumption, mL/kg/min 28.1 ± 4.7 (19.4–36.1)
Predicted peak oxygen consumption, % 57.4 ± 9.0 (36–73)
Oxygen consumption at the AT, mL/kg/min 8.0 ± 1.4 (5.5–10.3)
Maximum workload, W 11.1 ± 1.5 (7.4–12.4)
RVOT, right ventricular outflow tract; PR = pulmonary regurgitation; AT, anaerobic threshold; SD, standard deviation.
3.2. Procedural Characteristics
Almost all PPVI procedures were conducted via the transfemoral approach with general anesthesia
in 97.6% of subjects (Table 2), except one case of inferior vena cava interruption via right internal
jugular vein access. The largest 22 mm delivery system was used for 29 patients who underwent
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Melody valve implantation. Specifically, while the minimal RVOT diameter was 20.5 ± 2.9 mm
(range: 12–23 mm) prior to dilation, it increased to 22.1 ± 0.6 mm (range: 21.5–23 mm) thereafter.
In 57.1% of patients (24/42), the Melody valve was placed into a previously implanted bioprosthesis
(i.e., Carpentier-Edwards Perimount in eleven patients, Saint Jude Biocor and Epic in eleven, Hancock II
in one, Shelhigh in one, and Prima Plus in one). In eight subjects, frame fracture was attempted after
the achievement of a larger inner diameter and improved outcome. The RVOT was pre-stented in
ten (23.8%) patients, either prior to the procedure (one subject) or on the day of the implantation
(nine subjects). The Palmaz 4014 bare metal stent was chosen for most cases; however, the Cheatham
Platinum (CP) covered stent was used in two case due to severe supravalvular stenosis and extensive
calcification. In addition, valves with diameters of 26, 28, 30, and 32 mm were successively implanted in
one, three, two, and seven patients, respectively, as Pulsta valves. Valve sizes were decided according
to the measurement of the largest diameter of the target PA’s proximal, narrowest, and distal parts, as
well as its length assessed via cardiac CT, MRI, and echocardiography and balloon sizing of RVOT
simultaneously with RV angiography. The mean total procedural time was 95.3 ± 35.8 min, with a
mean fluoroscopy time of 35.2 ± 10.1 min.
Table 2. Procedural characteristics.
n/N (%) or Mean ± SD (Range)
General anesthesia 41/42 (97.6)
RVOT pre-stenting 10/42 (23.8)
Stent placed at the time of the procedure 9/10
Stent placed prior to the day of the procedure 1/10
Type of stent
Palmaz 4014 Bare metal stent 8/10
CP covered stent 2/10
Size of the implanted Melody valve (n = 29)
22 mm 29/29 (100)
Minimal diameter prior to pre-dilation 20.5 ± 2.9 (12–23)
Minimal diameter following pre-dilation 22.1 ± 0.6 (21.5–23)
Size of the implanted Pulsta valve (n = 13)
26 mm 1/13 (7.7)
28 mm 3/13 (23.1)
30 mm 2/13 (15.4)
32 mm 7/13 (53.8)
Valve-in-valve (previously implanted
bioprosthesis) procedure 28/42 (66.7)
Successful intentional BPV frame fracture 8/42 (19.0)
Length of procedure (min) 95.3 ± 35.8 (61–180)
Fluoroscopy time (min) 35.2 ± 10.1 (18.1–57.0)
RVOT, right ventricular outflow tract; CP, Cheatham Platinum; BPV, bioprosthetic valve; SD, standard deviation.
3.3. Periprocedural Outcomes and Complications during Follow-Up
Procedural success was defined as the implantation of a single valve in the intended location
and was reported to be 100.0% in the current study (Table 3). No infective endocarditis and valve
thrombosis were seen during the follow-up (mean: 14.2 months; range: 4–57 months). However,
transient periprocedural complications were observed in one patient as a stent dislocation, which was
successfully managed by repositioning without surgery and with the implantation of a Melody valve.
Nevertheless, no further procedural complications and mortality were reported, except for one case of
mortality due to unrelated complications that occurred during the follow-up period. Although PPVI
was completed without any adverse events, the patient’s underlying life-threatening comorbidities
and chronic renal failure were aggravated after the procedure; similarly, disseminated intravascular
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coagulation was not well tolerated. Finally, even though one case of Melody valve stent fracture was
diagnosed during the evaluation conducted at 46 months after the implantation, this was a type I
fracture [18], which did not require reintervention. We used pre-closure of large-sized sheath venous
access sites using single or double suture-mediated Perclose device in over 90% patients. Although the
diameter of the outer sheath in the valve loading zone is 22 Fr of Ensemble delivery system in Melody
valve, which is larger than the 18 F diameter in Pulsta valve system, all patients showed no significant
vascular complication or difficulty related to venous access.
Table 3. Procedural outcomes.
n/N (%) or Mean ± SD
Procedural success rate 42/42 (100.0)
Length of hospitalization, days 4.6 ± 0.7 (3–7)
Procedural complications
Major Valve dislocation 0 (0.0)
Conduit/RVOT rupture requiring operation 0 (0.0)
Intermediate Arrhythmia requiring treatment 0 (0.0)
Coronary compression 0 (0.0)
Stent dislocation 1 (2.4)
Minor Contained conduit rupture 1 (2.4)
Mild inguinal hematoma 1 (2.4)
Periprocedural and late mortality 1/42 (2.4)
Endocarditis 0/42 (0.0)
Stent fracture 1 1/42 (2.4)
RVOT, right ventricle outflow tract; SD, standard deviation. 1 Type 1, fracture of ≥ 1 strut without loss of stent
integrity [18].
3.4. Functional Outcomes
An improvement in hemodynamics and function was seen in patients following PPVI (Table 4).
By post-procedural day 30, the median peak systolic gradient over the RVOT measured by Doppler
recording on transthoracic echocardiography had fallen from 49.5 (preprocedural median) to
16 mmHg and slightly increased at 12 months without statistical significance (Figure 1). Specifically,
these improvements were more noticeable in the Melody valve group. A similar trend was observed in
right ventricular systolic pressure following Melody valve implantation. Furthermore, while 25 patients
(60%) had moderate-to-severe PR at baseline, no subjects displayed PR after PPVI. Quantitative analysis
of PR conducted with follow-up cardiac MRI also showed improvement in both the Melody and
the Pulsta valve groups (3.8 ± 5.3% and 4.7 ± 3.1%, respectively). Similarly, an improvement in
tricuspid regurgitation was noted, as 40% and 56% of patients showed absent or trivial PR at follow-up
day 30 and after 1 year, respectively (Figure 2). Follow-up cardiac MRI conducted 1 year after the
implantation revealed that the mean indexed RV end-diastolic volume had significantly decreased
to 118.8 ± 8.9 mL/m2 (range: 110–138 mL/m2) after PPVI (p = 0.003; Figure 3; Table 4). In addition,
the RV function (i.e., RV ejection fraction, which is determined by magnetic resonance imaging (MRI)
showed a tendency to increase from 44.3% ± 11.6% (range: 20–63%) before PPVI to 51.3 ± 5.1% (range,
47–59%; Figure 4) at 1 year follow-up. Although these results are consistent with previous research
showing no significant improvement in right ventricular ejection fraction (RVEF) after pulmonary
valve replacement, RV systolic function turns out to improve significantly as a direct consequence of
volume unloading after valve replacement especially when the RVEF was corrected for PR [19,20].
Moreover, the proportion of patients with NYHA class II (or higher) decreased from 85.7% at baseline
to 26.2% at 30 days, and only two patients (26.2; 7.7%) showed NYHA class II after 6 months (Figure 5).
Finally, both the VO2 and anaerobic threshold (AT) appeared to increase after PPVI; however, it should
be noted that these variables were difficult to interpret given the small number of patients included in
this study.
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patients over time.
Table 4. Hemodynamic and functional improvements following percutaneous pulmonary valve
implantation (PPVI).
Baseline Day 30 6 Months 1 Year 2 Years
Peak systolic gradient over
the RVOT (mmHg)
Melody 51.3 ± 11.5 16.7 ± 3.3 16.5 ± 4.5 17.5 ± 5.8 23.0 ± 6.6
(n = 29) (n = 29) (n = 22) (n = 12) (n = 8)
Pulsta
14.2 ± 1.5 11.3 ± 1.2 10.0 ± 0.0 11.7 ± 1.2
(n = 13) (n = 13) (n = 4) (n = 4)
p-value <0.001 0.25 0.32 0.31
RVSP across the tricuspid
valve (mmHg)
Melody 70.0 ± 16.8 41.3 ± 17.8
(n = 29) (n = 29)
Pulsta 41.8 ± 2.4(n = 13)





Melody 17.1 ± 13.6(n = 26)
3.8 ± 5.3
(n = 12)





Melody 137.5 ± 31.1(n = 26)
122.2 ± 8.3
(n = 12)








Class I 6/42 (14.3) 31/42 (73.8) 19/23 (82.6) 14/16 (87.5) 8/8 (100.0)
Class II 24/42 (57.1) 11/42 (26.2) 4/23 (17.4) 2/16 (12.5) 0/8 (0.0)
Class III 11/42 (26.2) 0/42 (0.0) 0/26 (0.0) 0/16 (0.0) 0/8 (0.0)
Class IV 1/42 (2.4) 0/42 (0.0) 0/26 (0.0) 0/16 (0.0) 0/8 (0.0)






Anaerobic threshold (mL/min/kg) 8.0 ± 1.4(n = 31)
9.1 ± 1.1
(n = 7)
Values are presented as either the number/N (%) or mean ± standard deviation (range). PPVI, percutaneous
pulmonary valve implantation; RVOT, right ventricular outflow tract; RVSP, right ventricular systolic pressure; PRF,
pulmonary regurgitation fraction, RVEDVi, indexed right ventricular end-diastolic volume, RVEF, right ventricular
ejection fraction; SD, standard deviation; NYHA, New York Heart Association. * Cardiac magnetic resonance
image-derived measurements.
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4. Discussion
In this study, we report the first experience of the utilization of both the balloon-expandable
Melody valve and the self-expandable Pulsta valve for the treatment of RVOT dysfunction in Korea,
in a relatively large sample population with an acceptable follow-up period. We successfully completed
valve implantation in all patients without any device-related adverse events. TPV function was well
maintained without any reintervention for a mean follow-up duration of 14.2 months.
Although the Melody valve was first implanted in a patient in the U.S. 13 years ago, reports
regarding the use of the Melody valve have been lacking in many countries around the world,
where the PPVI is still not routinely used and is in its introductory stage. Thus, this study is
meaningful in showing the results of recent treatment outcomes that reflect advances in the latest
technological experience.Indeed, the feasibility of the Pulsta valve for PPVI in Korea was first reported
by Kim et al. in 2018 [14]. Since its approval for PPVI in Korea in 2019, the valve has been increasingly
used. PPVI yields excellent early and short-term outcomes associated with a reduction in RVOT
obstruction, elimination of PR, and clinical improvement of functional class. Specifically, improved
circulatory efficiency and ventricular strain, enhanced cardiopulmonary exercise function in some
patients, and better quality of life after PPVI have all been suggested [21–24].
Furthermore, several noteworthy changes in implantation practices and outcomes have been
observed over time that likely reflect the learning curve effects, protocol modifications, and an evolving
understanding of better practices [25–28]. Previously, patients were more likely to undergo PPVI
with the smallest delivery systems (18 mm), which resulted in a high residual pressure gradient
across the RVOT and more frequent stent fractures and reinterventions [6,7]. Furthermore, in 2007,
Nordmeyer et al. reported a 21.1% (26 of 123) incidence rate of stent fractures after PPVI, which is
main cause of TPV dysfunction and has become less common since pre-stenting became more widely
implemented [18,25,29,30]. The indication of pre-stenting before PPVI with the Melody valve was to
secure the landing zone on previous RVOT and to prevent valve frame fracture. The relief of the residual
pressure gradient due to acute angulation or severe calcification on RVOT is also predominantly
obtained by the pre-stenting also in our study. For the majority of our patients who underwent a
valve-in-valve procedure, however, presenting was beneficial in case of resisting intrinsic or in situ
recoil of the fractured previous frame rather than to prevent stent fracture. As a pre-stent occupies
space within the previous bioprosthetic valve, potentially infringing on the achievable orifice area,
pre-stenting in previous BPV and non-dynamic RVOT is even more controversial [31]. The largest
22 mm Melody delivery system was employed in all cases in our study without significant residual
pressure gradient, while pre-stenting and/or the valve-in-valve procedure were performed in 29 (100%)
patients. As a result, only one case of type 1 fracture was observed. The efforts made to prevent and
reduce the occurrence of fractures of hemodynamically important valves are likely to yield even better
long-term outcomes than those documented in previous studies [5–7,32].
Conduit rupture is a relatively common adverse event of PPVI, which occurs in around 19.5–22%
of patients undergoing angioplasty [6,7]. As suggested in previous studies, we used a covered CP stent
(CCPS; NuMED, Inc., Hoptkinton, NY, USA) in one patient with severe supravalvular stenosis and
extensive calcification with luminal narrowing to prevent conduit injury and potential life-threatening
ruptures. However, to prevent fatal coronary arterial compression, we performed selective coronary
angiography with high-pressure balloon dilation to the maximal estimated diameter of the RVOT prior
to TPV implantation in all cases. Indeed, previous reports suggested endocarditis to be an important
adverse outcome during the follow-up period, however there is no endocarditis case reported in
our study.
Intentional bioprosthetic valve frame fracture was attempted in eight (34.8%) patients to prevent a
further decrease in the inner diameter (ID) that could potentially result in patient–prosthesis mismatch
and to achieve larger ID with better hemodynamics after PPVI [31]. Either the 25 mm Saint Jude Biocor
or the Epic valves had been previously used in seven patients, whereas the 23 mm Magna valve had
been implanted in one subject. Among the patients with the bioprosthetic valve’s fracture, the median
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final ID was 1 mm larger (0.5–3 mm) than the valve’s true ID. Similarly, the inflation pressure required
for the fracture varied between 18 and 20 atm (median 18 atm). Thereafter, Melody valves that were
22 mm in size were implanted in all subjects with a fractured frame, and no fracture-related adverse
events were observed.
Compared to other self-expandable systems undergoing human clinical trials, the Pulsta valve
has several unique advantages, including the knitted nitinol wire stent, which has a maximal length of
38 mm without bulkiness. Furthermore, the diameter of its outer sheath in the largest part of the TPV
loading zone is only 18 F (5.9 mm). Therefore, the Pulsta valve is fit for various dynamic native RVOT
lesions with significant PR given its low-profile delivery system and the softer nature of this device
compared to other self-expandable pulmonic valves. Definitely, the Pulsta valve could be promising as
a potential candidate for next-generation self-expandable valves for PPVI to minimize reintervention
rates [14].
Although the implementation of PPVI started relatively late in Korea compared to that in other
countries, considerable evidence has already accumulated through global experience. Encouragingly,
the early and midterm outcomes of PPVI reported at our institution were remarkable and comparable
to those in previous studies. In addition, in spite of the increasing use of these valves for non-conduit
RVOTs, there are still patients whose RVOTs are too large to accommodate currently existing
valve technology. Therefore, clinical trials on investigational devices, including the Venus p-valve,
Harmony and Alterra Pre-stent (with SAPIEN S3) valves, have been carried out [33–35]. We suggest
that the approval of the valves employed in our study, including the Pulsta valves, would greatly
support the recovery of patients with an RVOT dysfunction and improve the outcomes of those with
complex congenital heart diseases.
For one year of follow-up since 2019, in which the National Health Insurance reimbursement
coverage of percutaneous pulmonary valve and implantation were applied, a total of 78 cases underwent
successful valve insertion: 34 PPVI (34/78 = 43.6%) and 44 surgeries (44/78 = 56.4%). Overall, the reasons
for surgery included those patients who needed primary and additional surgery (n = 20/78; 25.6%)
due to tricuspid valvuloplasty, right ventricular outflow tract aneurysmectomy, or too small previous
conduits considering patients’ growth, those where the RVOT was a priori too large for PPVI (>32 mm)
(n = 18/78; 23.1%), and those with minor reasons (n = 6/78; 7.7%) including extensive acute endocarditis,
coronary compression during balloon interrogation, and patients’ personal choice. As the Pulsta valve
makes the procedure possible exceeding 28–29 mm of RVOT, a larger proportion of PPVI could be
performed successfully compared to surgery than reported so far [36].
Considering the retrospective acquisition of the data, missing data had a negative impact on
statistical significance. Furthermore, the small sample size included in the present investigation limited
the reliability of the available variables. The ongoing collection of data at later time points will help
to clarify longitudinal trends, and future studies with larger cohorts will augment to our findings.
Nevertheless, given the early stage of PPVI in Korea, limited data on outcomes at later time points are
available. More information will be obtained as the study continues with the follow-up of patients.
5. Conclusions
In conclusion, use of the Melody valve and the new self-expandable Pulsta valve for PPVI within
the native RVOT has a good safety profile and high efficacy in terms of both hemodynamic and
functional improvements. This appears to be comparable to previous reports with a potentially
reduced complication rate. Nevertheless, the endurance of such positive safety and efficacy outcomes
remains to be demonstrated over the longer term, as does device durability. This study showed,
for the first time in Korea, the successful implementation of PPVI in patients with various sizes of
RVOT. Continued data collection and initiation of larger registries in the future will add support for
our findings.
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